Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 2 Trials for Cladribine (DB00242)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02115295Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaTreatment
NCT03589729Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersSupportive Care